TippingPoint Biosciences, a therapeutic company focused on innovative drug discovery targeting the aberrant DNA in cancer cells, announced pre-seed investment from the Pediatric Brain Tumor Foundation, Sontag Foundation, Yuvaan Tiwari Foundation, and BrightEdge, the impact investment and venture capital arm of the American Cancer Society..

TippingPoint Biosciences是一家专注于针对癌细胞异常DNA的创新药物发现的治疗公司，宣布由儿科脑肿瘤基金会、桑塔格基金会、尤万·蒂瓦里基金会和BrightEdge（美国癌症协会的影响力投资和风险投资机构）进行种子前投资。。